Emergence of oseltamivir resistance: Control and management of influenza before, during and after the pandemic

Infectious Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 34-45

  Dixit, Rashmi ^a,b   Khandaker, Gulam ^a,b   Ilgoutz, Scott ^c   Rashid, Harunor ^a,b   Booy, Robert ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Influenza; Neuraminidase inhibitors; Oseltamivir; Pandemic; Resistance

Indexed keywords

OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ARTICLE; AUSTRALIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; HIGH RISK PATIENT; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA VIRUS A H1N1; MISSENSE MUTATION; PANDEMIC INFLUENZA; PUBLIC HEALTH; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; VIRAL PROTEINS; WORLD HEALTH; ZANAMIVIR;

EID: 84878756846     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/18715265112129990006     Document Type: Article

References (95)

1. Hurt, A. C.; Ho, H. T.; Barr, I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert. Rev. Anti Infect. Ther., 2006, 4 (5), 795-805.
2. Roche Australia, Tamiflu (oseltamivir phosphate) - Product statement. http://www.roche-australia.com/fmfiles/re7229005/downloads/anti-virals/tamiflu-pi.pdf (Accessed March 26, 2013).
3. Wang, M. Z.; Tai C. Y.; Mendel, D. B. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother., 2002, 46 (12), 3809-3816.
4. Santos, L.; Correia, V.; Giria, M.; Pedro, S.; Santos, M.; Silvestre, M. Genetic and antiviral drug susceptibility profiles of pandemic A(H1N1)v influenza virus circulating in Portugal. Presented at Options for the Control of Influenza VII; Hong Kong, SAR, China; Sept 3-7, 2010. Abstract O-851.
5. LeGoff, J.; Rousset, D.; Abou-Jaoudé, G.; Scemla, A.; Ribaud, P.; Mercier-Delarue, S.; Caro, V.; Enouf, V.; Simon, F.; Molina, J. M.; van der Werf, S. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One, 2012, 7 (8), e37095.
6. Van der Vries, E.; Stelma, F. F.; Boucher, C. A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med., 2010, 363 (14), 1381-1382.
7. Nguyen, H. T.; Fry, A. M.; Loveless, P. A.; Klimov, A. I.; Gubareva, L. V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis., 2010, 51 (8), 983-984.
8. Hurt, A. C.; Lee, R. T.; Leang, S. K.; Cui, L.; Deng, Y. M.; Phuah, S. P.; Caldwell, N.; Freeman, K.; Komadina, N.; Smith, D.; Speers, D.; Kelso, A.; Lin, R. T.; Maurer-Stroh, S.; Barr, I. G. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill., 2011, 16 (23), pii=19884.
9. Hurt, A. C.; Leang, S. K.; Speers, D. J.; Barr, I. G.; Maurer-Stroh, S. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg. Infect. Dis., 2012, 18 (1), 109-112.
10. Hurt, A. C.; Chotpitayasunondh, T.; Cox, N. J.; Daniels, R.; Fry, A. M.; Gubareva, L. V.; Hayden, F. G.; Hui, D. S.; Hungnes, O.; Lackenby, A.; Lim, W.; Meijer, A.; Penn, C.; Tashiro, M.; Uyeki, T. M.; Zambon, M.; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. Antiviral resistance during the 2009 influenza A H1N pandemic: public health, laboratory and clinical perspectives. Lancet Infect. Dis., 2012, 12 (3), 240-248.
11. Hauge, S. H.; Blix, H. S.; Borgen, K.; Hunges, O.; Dudman, S.; Aavitsland, P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007- 08. Virol. J., 2009, 6, 54.
12. Matsuzaki, Y.; Mizuta, K.; Aoki, Y.; Suto, A.; Abiko, C.; Sanjoh, K.; Sugawara, K.; Takashita, E.; Itagaki, T.; Katsushima, Y.; Ujike, M.; Obuchi, M.; Odagiri, T.; Tashiro, M. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol. J., 2010, 7, 53.
13. Meijer, A.; Lackenby, A.; Hungnes, O.; Lina, B.; van-der-Werf, S.; Schweiger, B.; Opp, M; Paget, J.; van-de-Kassteele, L.; Hay, A.; Zambon, M.; European Influenza Surveillance Scheme. Oseltamivir- resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis., 2009, 15 (4), 552-560.
14. Hauge, S. H.; Dudman, S.; Borgen, K.; Lackenby, A.; Hungnes, O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007- 08. Emerg. Infect. Dis., 2009, 15 (2), 155-162.
15. Stephenson, I.; Democratis, J.; Lackenby, A.; McNally, T.; Smith, J.; Pareek, M.; Ellis, J.; Bermingham, A.; Nicholson, K.; Zambon, M. Neuraminidase inhibitor resistance after oseltamivir treatmen of acute influenza A and B in children. Clin. Infect. Dis., 2009, 48 (4), 389-396.
16. Hurt, A. C.; Ernest, J.; Deng, Y. M.; Iannello, P.; Besselaar, T. G.; Birch, C.; Buchy, P.; Chittaganpitch, M.; Chiu, S. C.; Dwyer, D.; Guigon, A.; Harrower, B.; Kei, I. P.; Kok, T.; Lin, C.; McPhie, K.; Mohd, A.; Olveda, R.; Panayotou, T.; Rawlinson, W.; Scott, L.; Smith, D.; D'Souza, H.; Komadina, N.; Shaw, R.; Kelso, A.; Barr, I. G. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res., 2009, 83 (1), 90-93.
17. Yang, J. R.; Lin, Y. C.; Huang, Y. P.; Su, C. H.; Lo, J.; Ho, Y. L.; Yao, C. Y.; Hsu, L. C.; Wu, H. S.; Liu M. T. Reassortment and mutations associated with emergence and spread of oseltamivirresistant seasonal influenza A/H1N1 viruses in 2005-2009. PLoS One, 2011, 6 (3), e18177.
18. Centers for Disease Control and Prevention (CDC). 2008-2009 influenza season summary. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/08-09summary.htm (Accessed March 26, 2013).
19. Dharan, N. J.; Gubareva, L. V.; Meyer, J. J.; Okomo-Adhiambo, M.; McClinton, R. C.; Marshall, S. A.; St George, K.; Epperson, S.; Brammer, L.; Klimov, A. I.; Bresee, J. S.; Fry, A. M.; Oseltamivir- Resistance Working Group. Infections with oseltamivir-resistant Influenza A(H1N1) virus in the United States. J. A. M. A., 2009, 301 (10), 1034-1041.
20. Besselaar, T. G.; Naidoo, D.; Buys, A.; Gregory, V.; McAnerney, J.; Manamela, J. M.; Blumberg, L.; Schoub, B. D. Widespread Oseltamivir Resistance in Influenza A Viruses (H1N1), South Africa. Emerg. Infect. Dis., 2008, 14 (11), 1809-1810.
21. Tamura, D.; Mitamura, K.; Yamazaki, M.; Fujino, M.; Nirasawa, M.; Kimura, K.; Kiso, M.; Shimizu, H.; Kawakami, C.; Hiroi, S.; Takahashi, K.; Hata, M.; Minagawa, H.; Kimura, Y.; Kaneda, S.; Sugita, S.; Horimoto, T.; Sugaya, N.; Kawaoka, Y. Oseltamivirresistant influenza a viruses circulating in Japan. J. Clin. Microb., 2009, 47 (5), 1424-1427.
22. Cheng, P. K. C.; Leung, T. W. C.; Ho E. C. M.; Leung, P. C. K.; Ng, A. Y. Y.; Lai, M. Y. Y.; Lim, W. W. L. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis., 2009, 15 (6), 966-968.
23. Dia, N.; Niang, M. N.; Diadhiou, S. A.; Goudiaby, D. G.; Faye, A.; Kiori, D.; Bâ, M.; Michel, R.; Diop, O. M. Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal. B.M.C. Inf. Dis., 2013, 13, 106.
24. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. Morb. Mortal. Wkly. Rep., 2010, 59, 901-908.
25. Centres for Disease Control and Prevention (CDC). Update: influenza activity--United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. Morb. Mortal. Wkly. Rep., 2011, 60, 705-712.
26. Centres for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. Morb. Mortal. Wkly. Rep., 2012; 61, 414-420.
27. Centers for Disease Control and Prevention (CDC). Flu View. 2012-2013 Influenza Season Week 12 ending March 23, 2013. http://www.cdc.gov/flu/weekly/ (Accessed March 25, 2013).
28. Kawai, N.; Ikematsu, H.; Iwaki, N.; Kondou, K.; Hirotsu, N.; Kawashima, T.; Maeda, T.; Tanaka, O.; Doniwa, K.; Iwakuni, O.; Egashira, K.; Yamaji, K.; Kashiwagi, S. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. J. Infect. Chemother., 2012, 18, 180-186.
29. Health Protection Agency (HPA). Surveillance of influenza and other respiratory viruses in the UK: 2009-2010, 2010-2011, 2011- 2012, and 2013 weekly reports. http://www.hpa.org.uk/ (Accessed March 26, 2013).
30. EuroFlu. EuroFlu Electronic Bulletin.2009-13. http://www.euroflu.org/cgi-files/bulletin_v2.cgi (Accessed March 26, 2013).
31. Zhou, J.; Zou, L.; Zhang, X.; Liao, J.; Ni, H.; Hou, N.; Wang, Y.; Li, H.; Wu, J.; Jonges, M.; Meijer, A.; Koopmans, M.; Ke, C. Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009. J. Clin. Microb., 2011, 49 (7), 2651-2655.
32. Alfaresi, M.; Albedwawi, S.; Hag-Ali, M. Detection of an oseltamivir- resistant pandemic influenza A/H1N1 virus in the United Arab Emirates. Med. Princ. Pract., 2011, 20, 97-99.
33. Harvala, H.; Gunson, R.; Simmonds, P.; Hardie, A.; Bennett, S.; Scott, F.; Roddie, H.; McKnight, J.; Walsh, T.; Rowney, D.; Clark, A.; Bremner, J.; Aitken, C.; Templeton, K. The emergence of oseltamivir- resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November- December, 2009. Euro Surveill., 2010, 15 (14), pii: 19536.
34. Suppiah, J.; Yosuf, M. A.; Othman, K. A.; Saraswathy, T. S.; Thayan, R.; Kasim, F. M.; Murad, S.; Saat, Z. Monitoring of the h275y mutation in pandemic influenza A(H1N1) 2009 strains isolated in Malaysia. Southeast Asian J. Trop. Med. Public Health., 2011, 42 (1), 100-104.
35. Burrel, S.; Roncin, L.; Lafon, M. E.; Fleury, H. Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009. Euro Surveill., 2009, 14 (38), pii: 19334.
36. Souza, T. M. L.; Mesquita, M.; Resende, P.; Machado, V. Antiviral resistance surveillance for influenza A virus in Brazil: investigation on 2009 pandemic influenza A (H1N1) resistance to oseltamivir. Diag. Mic. Infec. Dis., 2011, 71 (1), 98-99.
37. Shin, S. Y.; Kang, C.; Gwak, J.; Kim, J. H.; Kim H. S.; Kang, Y. A.; Lee, K. G.; Kim J. S.; Lee, J.; Kim, S. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerg. Infect. Dis., 2011, 17 (4), 702-704.
38. Sheu, T. G.; Fry, A. M.; Garten, R. J.; Deyde, V. M.; Shwe, T.; Bullion, L.; Peebles, P. J.; Li, Y.; Klimov, A. I.; Gubareva, L. V. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J. Infect. Dis., 2011, 203 (1), 13-17.
39. Ujike, M.; Ejima, M.; Anraku, A.; Shimabukuro, K.; Obuchi, M.; Kishida, N.; Hong, X.; Takashita, E.; Fujisaki, S.; Yamashita, K.; Horikawa, H.; Kato, Y.; Oguchi, A.; Fujita, N.; Tashiro, M.; Odagiri, T. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg. Infect. Dis., 2011, 17 (3), 470-479.
40. Hurt, A. C.; Deng, Y.; Ernest, J.; Caldwell, N.; Leang, L.; Iannello, P.; Komadina, N.; Shaw, R.; Smith, D.; Dwyer, D. E.; Tramontana, A. R.; Lin, R. T.; Freeman, K.; Kelso, A.; Barr, I. G. Oseltamivirresistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill., 2011, 16 (3), pii: 19770.
41. Longtin, J.; Patel, S.; Eshaghi, A.; Lombos, E.; Higgins, R.; Alexander, D.; Olsha, R.; Doyle, J.; Tran, D.; Sarabia, A.; Lee, C.; Bastien, N.; Li, Y.; Low, D.; Boivin, G.; Gubbay, J. Neuraminidaseinhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada. J. Clin. Virol., 2011, 50, 257-261.
42. Ramirez-Gonzalez, J. E.; Gonzalez-Duran, E.; Alcantara-Perez, P.; Wong-Arambula, C.; Olivera-Diaz, H.; Cortez-Ortiz, I.; Barrera- Badillo, G.; Nguyen, H.; Gubareva, L.; Lopez-Martinez, I.; Díaz- Quiñonez, J. A.; Lezana-Fernández, M. A.; Gatell-Ramírez, H. L.; Cordova-Villalobos, J.A.; Hernández-Avila, M.; Alpuche-Aranda, C. Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerg. Infect. Dis., 2011, 17 (2), 283-286.
43. Calatayud, L.; Lackenby, A.; Reynolds, A.; McMenamin, J.; Phin, N.F.; Zambon, M. C.; Pebody, R. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg. Infect. Dis., 2011, 17 (10), 1807-1815.
44. Meijer, A.; Jonges, M.; Abbink, F.; Ang, W.; van Beek, J.; Beersma, M.; Bloembergen, P.; Boucher, C.; Claas, E.; Donker, G.; van Gageldonk-Lafeber, R.; Isken, L.; de Jong, A.; Kroes, A.; Leenders, S.; van der Lubben, M.; Mascini, E.; Niesters, B.; Oosterheert, J. J.; Osterhaus, A.; Riesmeijer, R.; Riezebos-Brilman, A.; Schutten, M.; Sebens, F.; Stelma, F.; Swaan, C.; Timen, A.; van 't Veen, A.; van der Vries, E.; teWierik, M.; Koopmans, M. Oseltamivir- resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009- 2010. Antiviral Res., 2011, 92 (1), 81-89.
45. Ledesma, J.; Vicente, D.; Pozo, F.; Cilla, G.; Castro, S. P.; Fernández, J. S.; Ruiz, M. P.; Navarro, J. M.; Galán, J. C.; Fernández, M.; Reina J.; Larrauri, A.; Cuevas, M. T.; Casas, I.; Breña, P. P. Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. J. Clin. Virol., 2011, 51 (3), 205-208.
46. Graitcer, S. B.; Gubareva, L.; Kamimoto, L.; Doshi, S.; Vandermeer, M.; Louie, J.; Waters, C.; Moore, Z.; Sleeman, K.; Okomo- Adhiambo, M.; Marshall, S. A.; St. George, K.; Pan, C.; La Plante, J. M.; Klimov, A.; Fry, A. M. Characteristics of patients with oseltamivir- resistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis., 2011, 17 (2), 255-257.
47. Payungporn, S.; Poomipak, W.; Makkoch, J.; Rianthavorn, P.; Theamboonlers, A.; Poovorawan, Y. Detection of oseltamivir sensitive/ resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand. J. Virol. Methods, 2011, 177 (2), 133-139.
48. Kourti, A.; Spanakos, G.; Politi, L.; Stavropoulou, A.; Spanakis, N.; Tsakris, A. Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010-2011 season. Int. J. Antimicrob. Ag., 2012, 40, 72-74.
49. Storms, A. D.; Gubareva, L. V.; Su Su; Wheeling, J. T.; Okomo- Adhiambo, M.; Pan, C.; Reisdorf, E.; St. George, K.; Myers, R.; Wotton, J. T.; Robinson, S.; Leader, B.; Thompson, M.; Shannon, M.; Klimov, A.; Fry, A. M. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis., 2012, 18 (2), 308-311.
50. Sleeman, K.; Sheu, T. G.; Moore, Z.; Kilpatrick, S.; Garg, S.; Fry, A. M.; Gubareva, L. V. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg. Infect. Dis., 2011, 17 (11), 2043-2046.
51. Miller, H. B.; Gose, R.B.; Nagata, M. T.; Sciulli, R. H.; Whelen, A. C. Pacific region influenza surveillance for oseltamivir resistance. J. Clin. Virol, 2012, 54, 73-75.
52. Hurt, A. C.; Hardie, K.; Wilson, N. J.; Deng, Y.; Osbourn, M.; Gehrig, N.; Kelso, A. Community transmission of oseltamivirresistant A(H1N1)pdm09 influenza. N. Engl. J. Med., 2011, 365 (26), 2541-2542.
53. Wang, B.; Taylor, J.; Ratnamohan, M.; McPhie, K.; Kesson, A.; Dixit, R.; Booy, R.; Hurt, A. C.; Saksena, N. K.; Dwyer, D. E. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. Euro Surveill., 2012, 17 (27), pii: 20210.
54. Hurt, A. C.; Hardie, K.; Wilson, N. J.; Deng, Y. M.; Osbourn, M.; Leang, S. K.; Lee, R. T. C.; Iannello, P.; Gehrig, N.; Shaw, R.; Wark, P.; Caldwell, N.; Givney, R. C.; Xue, L.; Maurer-Stroh, S.; Dwyer, D. E.; Wang, B.; Smith, D. W.; Levy, A.; Booy, R.; Dixit, R.; Merritt, T.; Kelso, A.; Dalton, C.; Durrheim, D.; Barr, I. G. Characteristics of a widespread community cluster of H275Y oseltamivir- resistant A(H1N1)pdm09 influenza in Australia. J. Infec. Dis., 2012, 206, 148-157.
55. Leang, S.; Deng, Y.; Shaw, R.; Caldwell, N.; Iannello, P.; Komadina, N.; Buchy, P.; Chittaganpitch, M.; Dwyer, D. E.; Fagan, P.; Gourinat, A.; Hammill, F.; Horwood, P. F.; Huang, Q. S.; Ip P. K.; Jennings, L.; Kesson, A.; Kok, T.; Kool, J. L.; Levy, A.; Lin, C.; Lindsay, K.; Osman, O.; Papadakis, G.; Rahnamal, F.; Rawlinson, W.; Redden, C.; Ridgway, J.; Sam, I.; Svobodova, S.; Tandoc, A.; Wickramasinghe, G.; Williamson, J.; Wilson, N.; Yusof, M. A.; Kelso, A.; Barr, I. G.; Hurt, A. C. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res., 2013, 97, 206-210.
56. Australian Government Department of Health and Ageing (DoHA). Australian influenza report 2012-29 September to 12 October 2012 (#10/2012) http://www.health.gov.au/internet/main/publishing.nsf/content/cda-surveil-ozflu-flucurr.htm (Accessed March 26, 2013).
57. World Health Organization (WHO) Regional Office For Europe. Epidemiological and virological situation update of the 2012/2013 influenza season in the WHO European Region. http://www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/influenza/publications/2013/epidemiological-and-virological-situationupdate-of-the-20122013-influenza-season-in-the-who-europeanregion
58. World Health Organization (WHO). Global Alert and Response (GAR). Influenza-like illness in the United States and Mexico. http://www.who.int/csr/don/2009_04_24/en/index.html (Accessed March 26, 2013).
59. World Health Organization (WHO). Update on oseltamivir resistance in influenza A(H1N1)2009 viruses. http://www.who.int/influenza/patient_care/antivirals/2011_09_23_weekly_web_update_oseltamivir_resistance.pdf (Accessed Mar 26, 2013).
60. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic (H1N1) 2009 - update 67. http://www.who.int/csr/don/2009_09_25/en/index.html (accessed March 26, 2013).
61. Eshaghi, A.; Patel, S.; Sarabia, A.; Higgins, R.; Savchenko, A.; Stojios, P.; Li, Y.; Bastien, N.; Alexander, D.; Low, D.; Gubbay, J. Multidrug-resistant influenza A(H1N1)pdm09 infection in immunocompetent child. Emerg. Infect. Dis., 2011, 17 (8), 1472-1474.
62. Ferraris, O.; Kessler, N.; Lina, B. Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res., 2005, 68 (1), 43-48.
63. Lin, C. H.; Huang, Y. C.; Chiu, Y. C.; Huang, C. G.; Tsao, K. C.; Lin, T. Y. Neurologic manifestations in children with influenza B virus infection. Pediatr. Infect. Dis. J., 2006, 25 (11), 1081-1083.
64. Hu, J. J.; Kao, C. L.; Lee, P. I.; Chen, C. M.; Lee, C. Y.; Lu, C. Y.; Huang, L. M. Clinical features of influenza A and B in children and association with myositis. J. Microbiol. Immunol. Infect.,2004, 37 (2), 95.
65. World Health Organization (WHO). Influenza update-09 September 2011 http://www.who.int/influenza/surveillance_monitoring/updates/2011_09_09_GIP_surveillance/en/ (Accessed Mar 26, 2013).
66. Renaud, C.; Boudreault, A.; Kuypers, J.; Lofy, K. H.; Corey, L.; Boeckh, M. J.; Englund, J.A. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg. Infect. Dis., 2011, 17 (4), 653-660.
67. Alonso, M.; Rodríguez-Sánchez, B.; Giannella, M; Catalán, P.; Gayoso, J.; López Bernaldo de Quirós, J.C.; Bouza, E.; García de Viedma, D. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J. Clin Virol., 2011, 50 (2), 114-118.
68. Carr, S.; Ilyushina, N.A.; Franks, J.; Adderson, E.E.; Caniza, M.; Govorkova, E. A.; Webster, R. G. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr. Infect. Dis. J., 2011, 30 (4), 284-288.
69. Wolfe, C.; Greenwald, I.; Chen, L. Influenza A(H1N1)pdm09 and oseltamivir resistance in hematology/oncology patients. Emerg. Infect. Dis., 2010, 16 (11), 1809-1811.
70. Fiore, A. E.; Shay, D. K.; Broder, K.; Iskander, J. K.; Uyeki, T. M.; Mootrey, G.; Bresee, J. S.; Cox, N. J.; Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. M. M. W. R. Recomm. Rep., 2009, 58 (RR-8), 1-52.
71. Kunisaki, K. M.; Janoff, E. N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis., 2009, 9 (8), 493-504.
72. Weinstock, D. M.; Gubareva, L. V.; Zuccotti, G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med., 2003, 348 (9), 867-868.
73. Klimov, A. I.; Rocha, E.; Hayden, F. G.; Shult, P. A.; Roumillat, L. F.; Cox, N. J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis., 1995, 172 (5), 1352-1355.
74. Ison, M. G.; Gubareva, L. V.; Atmar, R. L.; Treanor, J.; Hayden, F. G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis., 2006, 193 (6), 760-764.
75. Lackenby, A.; Moran Gilad, J.; Pebody, R.; Miah, S.; Calatayud, L.; Bolotin, S.; Vipond, I.; Muir, P.; Guiver, M.; McMenamin, J.; Reynolds, A.; Moore, C.; Gunson, R.; Thompson, C.; Galiano, M.; Bermingham, A.; Ellis, J.; Zambon, M. Continued emergence and changing epidemiology of oseltamivir-reistant influenza A (H1N1) 2009 virus, United Kingdom, winter 2010/11. Euro Surveill., 2011, 16 (5), pii: 19784.
76. Gaur, A. H.; Bagga, B.; Barman, S.; Hayden, R.; Lamptey, A.; Hoffman, J. M.; Bhojwani, D.; Flynn, P. M.; Tuomanen, E.; Webby, R. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N. Engl. J. Med., 2010, 362 (1), 88-89.
77. Dulek, D. E.; Williams, J. V.; Creech, C. B.; Schulert, A. K.; Frangoul, H. A.; Domm, J.; Denison, M. R.; Chappell, J. D. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis., 2010, 50 (11), 1493-1496.
78. McCaw, J. M.; Arinaminpathy, N.; Hurt, A. C.; McVemon, J.; McLean, A. R. A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model. PLoS Comput. Biol., 2011, 7 (4), e1002026.
79. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, Sept 28-Nov 29, 2008. Morb. Mortal. Wkly. Rep., 2008, 57 (49), 1329-1332.
80. Gubareva, L. V.; Kaiser, L.; Matrosovich, M. N.; Soo-Hoo, Y.; Hayden, F. G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis., 2001, 183 (4), 523-531.
81. Kiso, M.; Mitamura, K.; Sakai-Tagawa, Y.; Shiraishi, K.; Kawakami, C.; Kimura, K.; Hayden, F. G.; Sugaya, N.; Kawaoka, Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, 2004, 364 (9436), 759-765.
82. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir; last quarter 2007 to first quarter 2008. http://www.who.int/csr/disease/influenza/oseltamivir_summary/en/index.html. (Accessed January 02, 2011)
83. Rameix-Welti, M. A.; Enouf, V.; Cuvelier, F.; Jeannin, P.; van der Werf, S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog., 2008, 4 (7), e1000103.
84. Memoli, M. J.; Davis, A. S.; Proudfoot, K.; Chertow, D. S.; Hrabal, R. J.; Bristol, T.; Taubenberger, J. K. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis., 2011, 203 (3), 348-57.
85. Ives, J. A. L.; Carr, J. A.; Mendel, D. B.; Tai, C. Y.; Lambkin, R.; Kelly, L.; Oxford, J. S.; Hayden, F. G.; Roberts, N. A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res., 2002, 55 (2), 307-317.
86. Brookes, D. W.; Miah, S.; Lackenby, A.; Hartgroves, L.; Barclay, W. S. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J. Antimicrob. Chemother., 2011, 66 (3), 466-470.
87. Bloom, J. D.; Gong, L. I.; Baltimore, D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science, 2010, 328(5983), 1272-1275.
88. Hayden, F. G.; de Jong, M. D. Emerging influenza antiviral resistance threats. J. Infect. Dis., 2011, 203 (1), 6-10.
89. Centers for Disease Control and Prevention (CDC). Oseltamivirresistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. Morb. Mortal. Wkly. Rep., 2009, 58 (35), 969-972.
90. Moore, C.; Galiano, M.; Lackenby, A.; Abdelrahman, T.; Barnes, R.; Evans, M. R.; Fegan, C.; Froude, S.; Hastings, M.; Knapper, S.; Litt, E.; Price, N.; Salmon, R.; Temple, M.; Davies, E. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J. Infect. Dis., 2011, 203 (1), 18-24.
91. World Health Organisation (WHO). Influenza update - 09 September 2011 http://www.who.int/influenza/surveillance_monitoring/updates/2011_09_09_GIP_surveillance/en/ (Accessed March 26, 2013).
92. Esposito, S.; Molteni, C.G.; Daleno, C.; Valzano, A.; Fossali, E.; Da Dalt, L.; Cecinati, V.; Bruzzese, E.; Giacchino, R.; Giaquinto, C.; Galeone, C.; Lackenby, A.; Principi, N. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. Virol. J., 2010, 7, 202.
93. Booy, R.; Khandaker, G.; Heron, L. G.; Yin, J.; Doyle, B.; Tudo, K. K.; Hueston, L.; Gilbert, G. L.; Macintyre, C. R.; Dwyer, D. E. Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. Med. J. Aust., 2011, 194 (1), 19-23.
94. Butler, D. Portrait of a year-old pandemic. Nature, 2010, 464 (7292), 1112.
95. Nguyen, H. T.; Sheu, T.; Mishin, P.; Klimov, A.; Gubareva, L. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother., 2010, 54 (9), 3671-3677.